The Long, Winding Road of Immunotherapy Research
During his Presidential Address at the AACR Annual Meeting 2024, Philip D. Greenberg discussed research driving immunotherapy forward.
Author:
Neha J. Pancholi, PhD
During his Presidential Address at the AACR Annual Meeting 2024, Philip D. Greenberg discussed research driving immunotherapy forward.
Learn about synthetic lethality and approved drugs that use this approach to treat cancer.
The journey to the first approved TIL therapy began with Steven A. Rosenberg over 30 years ago.
Researchers discussed AI's impact on the diagnosis and treatment of cancer at the AACR Annual Meeting 2024.
The latest installment of this quarterly series highlights innovative research approaches reported at the AACR Annual Meeting 2024.
At the AACR Annual Meeting 2024, researchers discussed innovative approaches to decipher the complexities of tumor ecosystems.
Researchers at the AACR Annual Meeting 2024 presented the latest findings regarding two personalized neoantigen cancer vaccines.
Experts discussed "Discovery Science in Early Cancer Biology and Interception" at a plenary during the AACR Annual Meeting 2024.
Researchers at the Blood Cancer Discovery Symposium presented data on multidrug resistance and clinical trial design.
Patricia M. LoRusso and Stacy Shord discuss dosage optimization's current state and how the FDA-AACR workshop will move the...